New York, May 28, 2026, 16:01 (EDT)
Apyx Medical Corporation jumped 6.4% in late trading Thursday, up 25 cents to $4.15. The move brought some focus back to its Renuvion and AYON body-contouring products. Shares changed hands between $3.87 and $4.21. The market cap was near $174 million at the last price.
Apyx said Wednesday its latest update wasn’t an earnings release. The company announced “Body by Apyx” will return to Miami Swim Week, bringing Renuvion patients and featuring the AYON system. AYON combines Renuvion, liposuction, infiltration, aspiration and electrocautery on one platform. “The market continues to evolve,” said Regis Cain, senior director of marketing at Apyx, as patients look for more complete body-contouring. Apyx Medical
Apyx wants to show that AYON can be more than just a product story and start delivering on revenue. For the first quarter, Apyx posted $12.5 million in revenue, up from $9.4 million a year ago. The company also lifted its 2026 revenue target to $59 million to $60 million. Net loss narrowed to $2.1 million from $4.2 million and gross margin was 63.5%. CEO Charlie Goodwin called the quarter “continued execution” and said it backed the raised revenue outlook. Apyx Medical
The latest gains follow more clinical and regulatory headlines. Last week, Apyx said its small study—22 patients getting Avéli and Renuvion together—showed up to 81.8% had better cellulite at 180 days. Lead investigator Barry E. DiBernardo said dealing with cellulite and loose skin usually needs a “multi-modality approach.” Apyx Medical
Apyx got expanded FDA 510(k) clearance for its AYON device in May, adding power liposuction. The 510(k) pathway means the FDA saw it as substantially equivalent to an existing device—this is clearance, not premarket approval. Goodwin said Apyx plans a limited commercial launch of the added function ahead of wider rollout.
Apyx now sees more direct competition after launching AYON. In its annual filing, the company said it is up against established liposuction devices. Solta Medical, which is owned by Bausch Health, and MicroAire Surgical Instruments are listed as main rivals in the liposuction market.
Apyx traded stronger than the wider medical-device group Thursday. The iShares U.S. Medical Devices ETF added about 0.4%. InMode was up roughly 1.9%.
Aesthetics is also a factor. Reuters said this month that companies like Apyx and InMode want to capture demand from patients on GLP-1 weight-loss drugs, as rapid weight loss can cause loose skin. BMO Capital Markets analyst Evan Seigerman said U.S. conditions “could see an improvement” in the first and second quarters of 2026. Reuters
The deal still relies on execution. Apyx is not profitable and told investors it sees more losses ahead. The company said new equity could mean dilution for shareholders. Without enough capital on good terms, it may need to cut or delay sales, marketing, or product work. Cash and equivalents stood at $31.1 million as of March 31.
Right now, the stock faces one clear hurdle: can it turn recent momentum in AYON placements, Renuvion demand, and repeat handpiece sales into steadier orders? The runway event is a boost for the brand, but the numbers still need to deliver.
